Rare bleeding disorders have a huge impact on women’s lives.
Watch this expert-led, case-based webcast where our global faculty discuss the unmet needs in the identification and management of rare bleeding disorders in women and girls, with both pediatric and obstetric examples.
The live broadcast was on 22nd March 2022.
This webcast is suitable for global hematologists, pediatric hematologists, obstetricians/gynecologists, and primary care practitioners.
After participating in the live webinar learners will be able to:
- Identify the hallmark signs of rare bleeding disorders in women
- Debate the key barriers to early diagnosis and referral of rare bleeding disorders in women
- Explain how early diagnosis and timely referral can achieve optimum management
This program is made possible thanks to an independent educational grant from Novo Nordisk Health Care AG.
Welcome and introductions to the webcast
Unmet needs in the identification and management of rare bleeding disorders in women
Pediatric/adolescent case of girl with heavy menstrual bleeding: reaching a diagnosis and appropriate management
Obstetric case of woman with post-partum bleeding: reaching a diagnosis and appropriate management
|Unmet needs in the identification and management of rare bleeding disorders in women
|Practical approaches to achieving earlier diagnosis and referral, and optimum care: Case presentations
Pediatric/adolescent case of girl with heavy menstrual bleeding
Obstetric case of woman with post-partum bleeding
|Summary and close
DR ROSELINE D’OIRON
Roseline d’Oiron is currently a Medical Director at the Reference Centre for Hemophilia and Rare Congenital Bleeding Disorders, at APHP Université Paris Saclay, Hôpital Bicêtre, 94270 Le Kremlin–Bicêtre, France.
Dr d’Oiron graduated as a medical doctor from UFR Broussais-Hôtel-Dieu, University Paris VI, and completed her specialty training with master’s degrees in hematology, immunology, immunopathology, and transfusion medicine from UFR Saint-Antoine, University Paris VI.
Her research interests are principally in the area of hemophilia and rare bleeding disorders in both children and adults, especially regarding issues on molecular mechanisms of hemophilia A, inhibitors, immune tolerance, mild/moderate hemophilia, carriers of hemophilia, women with bleeding disorders and Glanzmann’s thrombasthenia.
Dr d’Oiron is the current elected president of the steering committee of the national FranceCoag registry on bleeding disorders. Dr d’Oiron is also a former elected member of the European Association for Hemophilia and Allied Disorders (EAHAD) Executive Committee. With the National Federation of Patients, she has developed outreach programs dedicated to women from families with hemophilia and rare bleeding disorders.
Roseline D’Oiron discloses the following relationships and financial interests. Grant or Research Support (to Hôpitaux Universitaires Paris-Sud, site Bicêtre, APHP) from Baxalta/Shire, CSL Behring, LFB, NovoNordisk, Octapharma, Pfizer, Roche and SOBI. Roseline also declares that she is on the advisory board or has been an invited speaker at symposia for the following companies Baxalta/Shire/Takeda, Bayer, Biomarin, CSL Behring, LFB, NovoNordisk, Octapharma, Pfizer, Roche, SOBI and Spark.
DR STACY CROTEAU
Dr Stacy Croteau is a pediatric hematologist and clinical investigator at Boston Children’s Hospital and an assistant professor of pediatrics at Harvard Medical School, where she specializes in bleeding and clotting disorders. Dr Croteau is the head of the Hemophilia/VWD program at Boston Children’s Hospital and Medical Director for the Boston Hemophilia Center serving Boston Children’s Hospital and Brigham and Women’s Hospital. Dr Croteau currently serves as the principal investigator for several industry-sponsored and investigator-initiated clinical trials on hemophilia and other bleeding and clotting disorders.
Stacy Croteau discloses the following relationships and financial interests: consultant fees from Biomarin, Bayer, CSL-Behring, Hema Biologics, Pfizer and Sanofi. She is also on the board of Directors for Hemophilia Alliance.
DR REZAN ABDUL-KADIR
Dr Rezan Abdul Kadir is a doctor and consultant obstetrician and gynaecologist at the Royal Free Hospital in London and University College London, UK. She is also a specialist consultant in women with bleeding disorders and set up the first multi-disciplinary clinic to provide comprehensive care for women and families with bleeding disorders. This clinic is renowned nationally and internationally for providing training and leading clinical and laboratory projects in this field.
Professor Abdul Kadir edited the book ‘Inherited Bleeding Disorders in Women’; first edition published in 2009 and second edition in 2019. She has authored/co-authored over two hundred peer-reviewed publications and written national and international guidelines in the field of thrombosis and haemostasis in women. She has acted as a guest editor and a reviewer for several journals, including Haemophilia, JTH, STH, IJOG, O&G, JOG and others. Professor Abdul Kadir is currently a co-chair of the women’s SSC committee of ISTH, a member of the women’s committee of the World Federation of Haemophilia (WFH) and European association for Haemophilia and Allied Disorders (EAHAD) and a member of the advisory board for the UK Haemophilia Society and the European Haemophilia Consortium (EHC).